Compare EIC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | SGHT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 235.0M |
| IPO Year | N/A | 2021 |
| Metric | EIC | SGHT |
|---|---|---|
| Price | $10.02 | $5.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $12.63 | $9.08 |
| AVG Volume (30 Days) | 86.3K | ★ 134.7K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.17 | $3.11 |
| 52 Week High | $13.92 | $9.24 |
| Indicator | EIC | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 65.14 |
| Support Level | $9.78 | $4.76 |
| Resistance Level | $10.15 | $5.66 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 13.92 | 76.25 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.